All In Biotech

Drug Trial Radar · NCT00146835

Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine

Phase IV, Prospective Study of the Safety of GSK Bios' Pediarix Administered to a Cohort of Infants in a US Health Maintenance Organization (HMO). (Post-Marketing PEDIARIX Safety Study)

Last checked: Nov 19, 2026Latest source record: Jan 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

120,794

Actual

Start

Apr 2003

Primary completion

Jun 2006

Study completion Jun 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Kaiser Permanente; University of California, Los Angeles
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 6 weeks, up to 9 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Pre-licensure studies of GSK Biologicals' PEDIARIX vaccine have shown it to be generally safe and unlikely to result in vaccine-associated serious adverse events. This post-licensure study is designed to evaluate relatively uncommon/rare outcomes in a large population cohort.

Conditions

  • Hepatitis B
  • Poliomyelitis
  • Diphtheria
  • Tetanus
  • Acellular Pertussis

Interventions

  • PediarixBiological

    1 or more injections

  • Licensed DTPa containing vaccineBiological

    1 or more injections

  • Prevnar®: (Wyeth)Biological

    Concomitant vaccination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All seizures following the primary doses of PEDIARIX in Cohort A and DTaP vaccine in Cohort BTime frame: During the 8-day period following the primary dose
  2. Medically-attended fever following the first dose of PEDIARIX in Cohort A and DTaP vaccine in Cohort BTime frame: Within 4 days following the first dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.